Lawsuit Challenges VOQUEZNA Market Exclusivity

Phathom Pharmaceuticals faces potential generic competition years early as BDR Pharmaceuticals contests FDA exclusivity.

Updated on Oct. 23, 2026 in Healthcare

Isometric editorial illustration of medicine vials in a grid, representing pharmaceutical market regulation and generic drug competition. — BDR Pharmaceuticals has sued the FDA to challenge a 2032 exclusivity ruling, potentially accelerating generic entry for Phathom Pharmaceuticals’ VOQUEZNA treatment. AI Illustration. Upload story photo >

Live Poll

Should federal regulators prioritize extending drug exclusivity periods to reward innovation over promoting generic competition?

BDR Pharmaceuticals has sued the FDA, challenging the agency's decision to grant VOQUEZNA market exclusivity until 2032. This legal action targets the regulatory barrier preventing the entry of generic competitors to Phathom Pharmaceuticals' treatment.

Why it matters

The lawsuit creates uncertainty regarding the long-term patent protections for blockbuster drugs. For operators in the pharmaceutical sector, the outcome will dictate the timeline for generic entry and the market dominance period for established brands.

Phathom Pharmaceuticals reported $175.1 million in 2025 net revenue, up 217% from $55.3 million in 2024. Shares have declined 67% year-to-date, including a 23% drop on October 23, 2026, following news of the lawsuit.

The players

BDR Pharmaceuticals

An international pharmaceutical company currently challenging FDA regulatory exclusivity findings.

Phathom Pharmaceuticals

A pharmaceutical company that markets VOQUEZNA and reported $175.1 million in 2025 net revenue.

FDA

The federal agency responsible for regulating drug approvals and enforcing market exclusivity periods.

The details

BDR Pharmaceuticals filed its challenge in the U.S. District Court for the District of Columbia after the FDA refused to accept an abbreviated new drug application for a generic version of VOQUEZNA. The company argues that the FDA improperly applied laws to extend exclusivity, which is currently scheduled to run until May 2032. An adverse court ruling could shorten this period and allow generic competition to enter the market years ahead of the current timeline.

May 2022: VOQUEZNA received its initial FDA approval.
Full-year 2025: Phathom Pharmaceuticals recorded $175.1 million in net revenue.
October 23, 2026: Phathom Pharmaceuticals shares fell approximately 23 percent.
May 2032: The current date for the expiration of VOQUEZNA exclusivity.

Market Landscape

The lawsuit tests the interpretation of the Hatch-Waxman Act's drug exclusivity provisions regarding generic drug entry. This litigation highlights ongoing industry friction regarding the FDA's application of statutory exclusivity periods for novel therapies.

Operators in the pharmaceutical and generic drug space should monitor this case for precedents concerning how the FDA calculates exclusivity windows. Decisions regarding product development timelines and generic pipeline investments should factor in the potential for early market shifts.

The takeaway

This case underscores the financial volatility inherent in drug exclusivity disputes for market participants. Stakeholders should track court filings in the District of Columbia to identify potential changes in the projected competitive landscape for VOQUEZNA.